摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4S)-4-amino-tetrahydrofuran-2-one

中文名称
——
中文别名
——
英文名称
(4S)-4-amino-tetrahydrofuran-2-one
英文别名
(4S)-4-aminodihydrofuran-2(3H)-one;(S)-4-aminodihydrofuran-2(3H)-one;(4S)-4-aminooxolan-2-one
(4S)-4-amino-tetrahydrofuran-2-one化学式
CAS
——
化学式
C4H7NO2
mdl
MFCD16658908
分子量
101.105
InChiKey
IFDRUMHFSJJIGX-VKHMYHEASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.1
  • 重原子数:
    7
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    52.3
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS FOR LOCAL DRUG DELIVERY<br/>[FR] MODULATEURS DES RÉCEPTEURS GLUCOCORTICOÏDES NON STÉROÏDIENS POUR ADMINISTRATION LOCALE DE MÉDICAMENTS
    申请人:LEO PHARMA AS
    公开号:WO2017046096A1
    公开(公告)日:2017-03-23
    The present invention relates to a compound according to formula (I) wherein R1 is selected from the group consisting of 5- and 6- membered heteroaryl, (C1- C6)alkyl, (C3-C6)cycloalkyl, (4-6)-membered heterocycloalkyl and phenyl; R2 is selected from (C1-C3)alkyl and halo(C1-C3)alkyl; R3 is selected from phenyl, 5-membered heteroaryl and 6-membered heteroaryl; R4 is selected from hydrogen, halogen, (C1- C4)alkyl and halo(C1-C4)alkyl; X1 is selected from CH, C(Rb) and N, X2 is selected from CH and N; Y is selected from -NH- and -O-; m is 0 or 1; n is 0 or 1; L represents a bond, -O-, -NH- or -N(RC)-; or pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.
    本发明涉及一种化合物,其化学式为(I),其中R1选自由5-和6-成员杂芳基、(C1-C6)烷基、(C3-C6)环烷基、(4-6)-成员杂环烷基和基;R2选自(C1-C3)烷基和卤代(C1-C3)烷基;R3选自基、5-成员杂芳基和6-成员杂芳基;R4选自、卤素、(C1-C4)烷基和卤代(C1-C4)烷基;X1选自CH、C(Rb)和N,X2选自CH和N;Y选自-NH-和-O-;m为0或1;n为0或1;L代表键,-O-,-NH-或-N(RC)-;或其药学上可接受的盐、合物或溶剂化合物。本发明还涉及用于制备所述化合物的中间体,用于治疗的该化合物,包含该化合物的药物组合物,使用该化合物治疗疾病的方法,以及使用该化合物制造药品的用途。
  • [EN] PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRROLOPYRIDAZINE UTILISÉS COMME INHIBITEURS DE KINASE
    申请人:GOSSAMER BIOSERVICES INC
    公开号:WO2022109492A1
    公开(公告)日:2022-05-27
    Described herein are inhibitors of JAK kinases, pharmaceutical compositions comprising them, processes for preparing them and uses of such inhibitors to treat or prevent diseases, disorders and conditions associated with kinase function.
    本文描述了JAK激酶抑制剂,包括它们的制药组合物、制备它们的过程以及使用这些抑制剂来治疗或预防与激酶功能相关的疾病、紊乱和病况。
  • Design, synthesis and evaluation of novel deferasirox derivatives with high antifungal potency in vitro and in vivo
    作者:Tingjunhong Ni、Xiaochen Chi、Hao Wu、Fei Xie、Junhe Bao、Jiayin Wang、Zhe Ji、Liping Li、Xiaobo Wang、Lan Yan、Yumeng Hao、Dazhi Zhang、Yuanying Jiang
    DOI:10.1016/j.ejmech.2023.116026
    日期:2024.1
    Here we designed and synthesized 58 deferasirox derivatives with the aim of discovering novel antifungal agents. Most compounds exhibited moderate to excellent in vitro antifungal activities against Cryptococcus neoformans H99 with MIC values ranging from 0.25 μg/mL to 16 μg/mL, including ten compounds with MIC values less than 1 μg/mL that were further screened against an additional six pathogenic
    在这里,我们设计并合成了 58 种地拉罗司生物,旨在发现新型抗真菌药物。大多数化合物对新型隐球菌H99 表现出中等至优异的体外抗真菌活性,MIC 值范围为 0.25 μg/mL 至 16 μg/mL,其中 10 种化合物的 MIC 值小于 1 μg/mL,并针对另外 6 种致病菌进一步筛选。菌类。此类化合物对光滑念珠菌表现出高效力,MIC 值范围为 <0 id=98>54,对 14 种光滑念珠菌菌株具有高效力。和隐球菌属。 MIC 值范围为 <0 id=101>54,在 10 mg/kg 剂量下,显着降低了新型隐球菌H99播散性感染小鼠模型中的 CFU ,与 FLC 相当。目前正在对化合物54进行进一步研究。
  • N-HETERO-RING-SUBSTITUTED AMIDE DERIVATIVE
    申请人:Daiichi Sankyo Company, Limited
    公开号:EP2738168B1
    公开(公告)日:2016-04-06
  • HVIDT, TORSTEN;SZAREK, WALTER A.;MACLEAN, DAVID B., CAN. J. CHEM., 66,(1988) N 4, 779-782
    作者:HVIDT, TORSTEN、SZAREK, WALTER A.、MACLEAN, DAVID B.
    DOI:——
    日期:——
查看更多